Navigation Links
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Date:11/16/2007

Food and Drug Administration approval for this indication.

"The skin clearance we have seen in HUMIRA psoriasis clinical trials, combined with ten years of clinical experience across indications and the convenience of self-injection, make HUMIRA a much anticipated treatment option for this condition," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development at Abbott.

About HUMIRA Psoriasis Clinical Trials

The opinion is primarily based on the results of two randomized, controlled, multi-center clinical trials in adult patients: REVEAL and CHAMPION. In both trials, the signs and symptoms of psoriasis were measured and evaluated using the Psoriasis Area and Severity Index (PASI) among other measures. CHAMPION was the first head-to-head study comparing a biologic medication to methotrexate, the standard systemic treatment for psoriasis.

-- In REVEAL, a pivotal 52-week trial, the short-term and sustained

clinical efficacy and safety of HUMIRA were evaluated in more than

1,200 patients from the United States and Canada with moderate to

severe chronic plaque psoriasis. Patients experienced a significant

reduction in the signs and symptoms of their disease at 16 weeks when

treated with HUMIRA. Specifically, almost three out of four patients

(71 percent) receiving HUMIRA achieved PASI 75 (75 percent or better

improvement in PASI), compared to 6.5 percent of patients receiving

placebo.

One in five patients (20 percent) receiving HUMIRA achieved

PASI 100 (complete clearance), compared to 1 percent of patients

receiving placebo. For patients who maintained a PASI 75 response

after eight months of continuous HUMIRA therapy, patients were either

continued on HUMIRA or administered placebo for the remainder of the

study. Significantly fewer patients (5 percent) on HUMIRA lost


'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 The California Healthcare ... organization representing leading California academic institutions, biotechnology, medical ... US today released a report revealing that ... growth. The trend shows a 4 percent increase ... Biomedical Industry Report indicates that, while biopharmaceutical ...
(Date:11/21/2014)... 2014 Why did Stephen Hawking become ... so instantly recognizable? Why have they become icons to ... author Hilton Ratcliffe seeks out the answers to those ... to do with science. In " Stephen Hawking Smoked ... 21, 2014), Ratcliffe puts it plainly: , “It ...
(Date:11/21/2014)... /CNW/ - Aequus Pharmaceuticals Inc. (the "Company" or ... closed a brokered private placement offering (the "Brokered ... Cormark Securities Inc. and Clarus Securities Inc. acted ... a syndicate of agents that also included Wolverton ... "Agents"). Concurrently with the Brokered Offering, the Company ...
(Date:11/18/2014)... Sarasota, FL (PRWEB) November 17, 2014 ... novel point-of-care diagnostic tests – today announces its ... Control and Prevention’s (CDC) Get Smart About Antibiotics ... Antibiotics Week is a national campaign designed to ... local health departments, and non-profit and for-profit partners ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... TOKYO, Japan, October 14 Sosei ... company,today announces the assignment of the drug discovery ... UK biotechnology company and subsidiary of,PepTcell Limited. These ... were shown by Sosei to have pronounced anti-inflammatory ...
... 13 SpectraScience, Inc. (OTC Bulletin Board: SCIE), a ... it has engaged Bielderman BVBA, an experienced European contract ... Barrett,s esophageal cancer application under trial at certain European ... Company,s application to the Food and Drug Administration ("FDA") ...
... CPHD ) today announced that it will report financial ... Wednesday, October 28, 2009, after the close of the market. ... p.m. Pacific Time on Wednesday, October 28, 2009, to discuss ... Cepheid,s website at www.cepheid.com/investors at least ...
Cached Biology Technology:Sosei Announces Deal With UK Biotech Company 2SpectraScience Engages European Contract Research Organization to Manage Clinical Trials 2SpectraScience Engages European Contract Research Organization to Manage Clinical Trials 3Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast 2
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... Translational Genomics Research Institute (TGen) is presenting two key studies, ... Cancer, July 3-7 in Amsterdam. One study, presented July ... effectiveness of the most common combination chemotherapy given to patients ... today, July 7, suggests that combination drug therapy may be ...
... boy bands of Americathere,s a new group in town. ... San Diego, California, entered The Christopher Columbus Awards Competition, ... challenges middle-school students to identify a community problem and ... from the popular group the Backstreet Boys, the students ...
... Researchers at the John Theurer Cancer Center recently published a ... stem cell transplants. Scott Rowley, M.D., Chief, Blood & Marrow ... Hackensack University Medical Center contributed to the study which was ... was published in the Journal of Consulting and Clinical ...
Cached Biology News:TGen presents lung cancer studies at Amsterdam conference 2Middle-school students educate community on proper computer posture 2John Theurer Cancer Center BMT researchers highlight the importance of social support 2
... by Stoelting, selects single cells, or clusters, ... time at all, a single cell can ... cell is collected into the pipette, and ... a microtiter plate. Quixells unique aspiration and ...
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Viruses microRNA Microarray contains ...
... At the forefront of Agilent analytical solutions ... local area networking (LAN) allows you to ... fast and informed decision making. Just as ... all the flexibility and performance needed for ...
The novel and unique HCTplus delivers unmatched information-rich data-dependent LC/MSn data for todays challenge in proteomics and metabonomics work....
Biology Products: